Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs
| Status: | Recruiting |
|---|---|
| Conditions: | Skin Cancer, Endocrine |
| Therapuetic Areas: | Endocrinology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | June 2011 |
| Contact: | Hershel Bhadsavle |
| Email: | hershel.bhadsavle@cshs.org |
| Phone: | (310) 423-2830 |
Hormonal and Metabolic Responses to Oral Glucose During Somatostatin Analog Use
The purpose of this study is to test the effect of long-acting somatostatin analog
medications, taken by patients with acromegaly or carcinoid syndrome, on growth hormone in
comparison to healthy controls who are not receiving the medication in order to see whether
or not the medication makes the oral glucose test less accurate. The Oral Glucose Tolerance
Test (OGTT) is a standard test to measure growth hormone secretion. By comparing GH
responses in non-acromegaly subjects taking somatostatin analog treatment, the relative
contribution of the medication and the underlying disease state can be analyzed.
medications, taken by patients with acromegaly or carcinoid syndrome, on growth hormone in
comparison to healthy controls who are not receiving the medication in order to see whether
or not the medication makes the oral glucose test less accurate. The Oral Glucose Tolerance
Test (OGTT) is a standard test to measure growth hormone secretion. By comparing GH
responses in non-acromegaly subjects taking somatostatin analog treatment, the relative
contribution of the medication and the underlying disease state can be analyzed.
Subjects will be informed of the study and after providing written informed consent,
subjects will be asked to undergo a 2-hour oral glucose tolerance test (ingestion of 75g
glucose with subsequent timed assessment of growth hormone, glucose, insulin and related
binding proteins.) Baseline assessment of hormones that may contribute to the results will
be drawn, prior to performing the test. Patients will be asked to complete one visit total
to participate in this trial.
subjects will be asked to undergo a 2-hour oral glucose tolerance test (ingestion of 75g
glucose with subsequent timed assessment of growth hormone, glucose, insulin and related
binding proteins.) Baseline assessment of hormones that may contribute to the results will
be drawn, prior to performing the test. Patients will be asked to complete one visit total
to participate in this trial.
Inclusion Criteria:
- Diagnosis of acromegaly or carcinoid syndrome
- Treatment with somatostatin analog therapy (must have established a stable dose of
three or more injections on the same dose prior to study enrollment)
- Healthy control subjects
Exclusion Criteria:
- Diagnosis of Diabetes Mellitus (Type 1 or Type 2)
- Use of medication for the treatment of insulin resistance or diabetes
We found this trial at
1
site
Click here to add this to my saved trials
